SNCA and Parkinson disease: The treatment of Parkinson’s disease targets α-synuclein to reduce aggregation and dopamine degradation by utilizing monoamine oxidase B inhibitors (MAO-B), neuroinflammation, and iron accumulation to decrease oxidative stress and neuronal cell death [14,15,16,17].